Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Defining the sites of interaction for corrector molecules on wildtype- and F508del-mutant cystic fibrosis transmembrane conductance regulator protein

FY 2022-23

Summary
Cystic fibrosis (CF) is a genetic disease that primarily impacts the lungs, leading to increased risks of airway infection and inflammation. Those with CF bear a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) protein (acts as a channel for ion movement in cells). Most CF individuals have a mutation in CFTR called F508del, leading to less functional CFTR protein being fully processed in cells. However, there are several drugs that can help restore mutant CFTR to its functional, mature form. One such type is called correctors, such as lumacaftor (VX-809) and elexacaftor (VX-445), which help restore full CFTR processing. Correctors, in use with another drug type called potentiators (help restore CFTR’s channel activity), form a drug combination (Trikafta) that is approved for clinical use in F508del-individuals. A recent study has shown the interaction sites of VX-809 on normal CFTR isolated from cells, however this has not been studied for VX-809 or VX-445 on F508del-CFTR in their natural environment. My goal is to identify the sites where VX-809 and VX-445 bind onto F508del-CFTR within cellular membranes. Our lab (in collaboration with our colleagues) has developed probes based off each corrector’s structure, allowing for permanent binding to their interaction site on CFTR. Thus, we will first validate that the probes are functionally similar to their parent compound in restoring F508del-CFTR to its mature form, and confirm that they can permanently bind to CFTR. We will then analyze the specific interaction sites of the probes on CFTR, as well as verify each site by performing CFTR mutation experiments. This probe-binding study can help to assess the binding of many correctors to F508del-CFTR, as well as to other similar CFTR mutant forms.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486619
Name
Auw-Yang Kevin T
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Defining the sites of interaction for corrector molecules on wildtype- and F508del-mutant cystic fibrosis transmembrane conductance regulator protein
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biological Membrane; Cftr; Channel Function Assays; Corrector Compounds; Cystic Fibrosis; F508del; Photoactivatable Probes; Rare Mutations; Site Of Drug Interaction
Abstract
Cystic fibrosis (CF) is a genetic disease that primarily impacts the lungs, leading to increased risks of airway infection and inflammation. Those with CF bear a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) protein (acts as a channel for ion movement in cells). Most CF individuals have a mutation in CFTR called F508del, leading to less functional CFTR protein being fully processed in cells. However, there are several drugs that can help restore mutant CFTR to its functional, mature form. One such type is called correctors, such as lumacaftor (VX-809) and elexacaftor (VX-445), which help restore full CFTR processing. Correctors, in use with another drug type called potentiators (help restore CFTR’s channel activity), form a drug combination (Trikafta) that is approved for clinical use in F508del-individuals. A recent study has shown the interaction sites of VX-809 on normal CFTR isolated from cells, however this has not been studied for VX-809 or VX-445 on F508del-CFTR in their natural environment. My goal is to identify the sites where VX-809 and VX-445 bind onto F508del-CFTR within cellular membranes. Our lab (in collaboration with our colleagues) has developed probes based off each corrector’s structure, allowing for permanent binding to their interaction site on CFTR. Thus, we will first validate that the probes are functionally similar to their parent compound in restoring F508del-CFTR to its mature form, and confirm that they can permanently bind to CFTR. We will then analyze the specific interaction sites of the probes on CFTR, as well as verify each site by performing CFTR mutation experiments. This probe-binding study can help to assess the binding of many correctors to F508del-CFTR, as well as to other similar CFTR mutant forms.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Auw-Yang, Kevin T
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~